Related Experiment Video
Updated: Mar 31, 2026
Author Spotlight: Assessing the Feasibility of Using Amplitude-Integrated EEG During Neonatal Transport
Published on: June 21, 2024
Prospective Surveillance of Extreme Neonatal Hyperbilirubinemia in Australia
Angela McGillivray1, Jan Polverino1, Nadia Badawi2
1Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; The University of Sydney, Sydney, New South Wales, Australia.
Insights
The incidence of extreme neonatal hyperbilirubinemia in Australia is 9.4 per 100,000 live births. Prevention strategies, including universal glucose-6-phosphate dehydrogenase screening, are crucial to avoid neurodisability.
Area of Science:
- Neonatal Medicine
- Pediatrics
- Public Health
Background:
- Extreme neonatal hyperbilirubinemia poses a risk for neurodevelopmental impairment.
- Accurate incidence data and etiological understanding are vital for effective prevention strategies.
Purpose of the Study:
- To determine the incidence, causes, associated factors, and short-term outcomes of extreme neonatal hyperbilirubinemia in Australia.
- To identify opportunities for preventing this condition and its potential complications.
Main Methods:
- A prospective, population-based surveillance study was conducted in collaboration with the Australian Pediatric Surveillance Unit from April 2010 to March 2013.
- Infants >34 weeks gestation with peak total serum bilirubin ≥450 μmol/L or clinical evidence of bilirubin encephalopathy met the case definition.
- Clinicians completed questionnaires detailing demographic, clinical, etiological, management, and outcome data.
Main Results:
- The estimated incidence of extreme neonatal hyperbilirubinemia in Australia was 9.4 per 100,000 live births.
- Common etiologies included idiopathic ABO incompatibility, glucose-6-phosphate dehydrogenase deficiency, and Rhesus isoimmunization.
- Hemolytic etiologies were significantly associated with extremely high bilirubin levels (P < .002).
Conclusions:
- The Australian incidence aligns with previous international studies.
- Robust assessment and management strategies before and after hospital discharge are essential for preventing neurodisability.
- Universal glucose-6-phosphate dehydrogenase screening and regular bilirubin monitoring could enhance preventative measures.
Objectives:
To determine the incidence, causes, associated factors, and short-term outcomes of extreme neonatal hyperbilirubinemia in Australia in order to identify opportunities for prevention.
Study Design:
This was a prospective population-based surveillance study in collaboration with the Australian Pediatric Surveillance Unit between April 1, 2010, and March 31, 2013. Case definition was: infants >34 weeks gestation with a peak total serum bilirubin ≥450 μmol/L and or clinical evidence of bilirubin encephalopathy. Clinicians completed questionnaires detailing demographic and clinical data including: peak serum bilirubin, signs of bilirubin encephalopathy, etiology, associated pathology, management, and short-term outcomes.
Results:
The questionnaire return rate was 95%, and 87 infants met the case definition. The Australian incidence of extreme neonatal hyperbilirubinemia is estimated to be 9.4/100,000 live births. Main etiologies were: idiopathic ABO blood group incompatibility, glucose-6-phosphate dehydrogenase deficiency, and Rhesus isoimmunization. There were no significant differences in short-term outcomes between inpatient and outpatient cases. Cases with a hemolytic etiology were significantly more likely to have extremely high levels of hyperbilirubinemia (P < .002).
Conclusion:
The incidence of extreme neonatal hyperbilirubinemia in Australia is comparable with previous studies. Robust pre- and post-discharge assessment and management strategies of neonatal hyperbilirubinemia are essential to prevent neurodisability. Universal glucose-6-phosphate dehydrogenase screening and serial bilirubin monitoring may optimize preventative strategies.
